Regen BioPharma Inc SEC filings RGBPP
Regen BioPharma Inc has 263 filings in SEC EDGAR's recent list, going back to Oct 15, 2013. Its latest annual report, Form 10-K, was filed on Dec 30, 2025 for the period ended Sep 30, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 17, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 2, 2026 (material agreement). The company's fiscal year ends on September 30.
| Form | Description | Filed | Period |
|---|---|---|---|
| NT 10-Q | Filing | Aug 13, 2026 | Jun 30, 2026 |
| QUALIF | Filing | Jan 12, 2026 | — |
| 1-A POS | Filing | Jan 8, 2026 | — |
| 253G1 | Filing | Dec 5, 2025 | — |
| QUALIF | Filing | Dec 3, 2025 | — |
| CORRESP | Letter to the SEC | Dec 1, 2025 | — |
| 1-A | Filing | Nov 17, 2025 | — |
| 253G1 | Filing | Sep 8, 2025 | — |
| QUALIF | Filing | Sep 5, 2025 | — |
| CORRESP | Letter to the SEC | Sep 4, 2025 | — |
| UPLOAD | Letter from the SEC | Sep 4, 2025 | — |
| 1-A | Filing | Aug 29, 2025 | — |
| 1-A-W | Filing | Aug 12, 2025 | — |
| 15-15D/A | Filing | May 29, 2025 | — |
| 1-A POS | Filing | Mar 3, 2025 | — |
| 253G1 | Filing | Feb 24, 2025 | — |
| 15-15D/A | Filing | Dec 31, 2024 | — |
| 15-15D | Filing | Dec 26, 2024 | — |
| QUALIF | Filing | Dec 10, 2024 | — |
| CORRESP | Letter to the SEC | Dec 9, 2024 | — |
| CORRESP | Letter to the SEC | Nov 21, 2024 | — |
| 1-A/A | Filing | Nov 21, 2024 | — |
| UPLOAD | Letter from the SEC | Nov 7, 2024 | — |
| 1-A/A | Filing | Oct 28, 2024 | — |
| UPLOAD | Letter from the SEC | Sep 26, 2024 | — |
| 1-A | Filing | Sep 16, 2024 | — |
| EFFECT | Filing | Sep 29, 2023 | — |
| UPLOAD | Letter from the SEC | Sep 27, 2023 | — |
| CORRESP | Letter to the SEC | Sep 27, 2023 | — |
| RW | Filing | Jul 24, 2023 | — |
| EFFECT | Filing | May 12, 2023 | — |
| CORRESP | Letter to the SEC | May 11, 2023 | — |
| CORRESP | Letter to the SEC | May 2, 2023 | — |
| UPLOAD | Letter from the SEC | Apr 27, 2023 | — |
| NT 10-Q/A | Filing | May 24, 2019 | Mar 31, 2019 |
| NT 10-Q | Form nt 10-q | May 14, 2019 | Mar 31, 2019 |
| NT 10-K | Form nt 10-k | Dec 28, 2017 | Sep 30, 2017 |
| UPLOAD | Letter from the SEC | May 2, 2017 | — |
| CORRESP | Letter to the SEC | Apr 28, 2017 | — |
| CORRESP | Letter to the SEC | Mar 30, 2017 | — |
| CORRESP | Letter to the SEC | Mar 22, 2017 | — |
| UPLOAD | Letter from the SEC | Mar 9, 2017 | — |
| NT 10-K | Form nt 10-k | Dec 30, 2015 | Sep 30, 2015 |
| EFFECT | Filing | Mar 18, 2014 | — |
| CORRESP | Letter to the SEC | Mar 4, 2014 | — |
| CORRESP | Letter to the SEC | Jan 29, 2014 | — |
| CORRESP | Letter to the SEC | Jan 14, 2014 | — |
| UPLOAD | Letter from the SEC | Dec 5, 2013 | — |
| CORRESP | Letter to the SEC | Nov 22, 2013 | — |
| UPLOAD | Letter from the SEC | Nov 8, 2013 | — |
Showing 50 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RGBP (OTC), RGBPP (OTC)
- Fiscal year ends
- September 30
- Incorporated in
- NV
- Headquarters
- La Mesa, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1589150
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.